Pancreatitis is a common inflammation of the pancreas with rising incidence in many countries. Despite improvements in diagnostic techniques, the disease is associated with high risk of severe morbidity and mortality and there is an urgent need for new therapeutic interventions. In this study, we evaluated whether histone deacetylases (HDACs), key epigenetic regulators of gene transcription, are involved in the development of the disease.
Introduction
Abnormal activity of histone deacetylases (HDACs), a family of enzymes involved in the epigenetic control of gene transcription, has been implicated in the aetiology and development of several malignancies. However, recent evidence indicates that HDACs are also involved in the development of inflammatory diseases, highlighting the potential of targeting the activity of HDACs as a therapeutic approach to improve the outcome of rheumatoid arthritis (Choo et al., 2010 (Choo et al., , 2013 , neuritis (Zhang et al., 2010; Zhang and Schluesener, 2013) , cholitis (Felice et al., 2015) and autoimmunity (Hancock et al., 2012) .
HDACs control the acetylation status of histone and non-histone proteins, thus regulating the expression of target genes (reviewed in Delcuve et al., 2012) . The complexity of acetylation-based epigenetic regulation is reflected by the size of the mammalian HDAC family, composed of 11 zinc-dependent enzymes divided into three subfamilies (classes I, II and IV) and seven NAD-dependent enzymes in a fourth (sirtuin) subfamily (class III), with non-redundant functions.
The function of HDAC subfamilies in the pathophysiology of pancreatitis, a highly debilitating inflammatory disease with a potentially lethal outcome, has not been thoroughly investigated. During pancreatitis, the organ is infiltrated by different leukocyte populations, with the most abundant being neutrophils, macrophages, T cells and dendritic cells. The differentiation and activation of these cell types are regulated by HDAC activity (Nencioni et al., 2007; Bartels et al., 2010; Roger et al., 2011) . In addition, acinar cell proliferation and consequent organ regeneration is observed following inflammatory damage. This regenerative process is characterized by reactivation of a developmental-like programme (Jensen et al., 2005; Ziv et al., 2013; Murtaugh and Keefe, 2015) , the regulation of which is still elusive. Based on these observations, we hypothesize that HDAC activity may be a key factor in modulating not only leukocyte infiltration in the injured tissue but also gene expression changes in acinar cells affecting pancreatic regeneration. In support of this hypothesis, two recent studies showed that in vivo treatment with the pan-HDAC inhibitors sodium butyrate and trichostatin A (TSA), which target both class I and class II HDAC subfamilies, alleviated pancreatic damage, inflammation and fibrosis following L-arginine- (Kanika et al., 2015) or taurocholic acid-induced pancreatitis (Hartman et al., 2015) in rodents. However, in another study treatment with valproic acid had a detrimental effect on cerulein-induced pancreatitis, consequently delaying tissue recovery and reducing acinar cell proliferation (Eisses et al., 2015) . These conflicting results highlight the need to further investigate the precise role of HDAC isoforms in this disease.
In this study, we examined the temporal regulation of HDACs in different murine models of acute, chronic and autoimmune pancreatitis (AIP). Furthermore, we evaluated the therapeutic potential of class I HDAC inhibition to modulate pancreatic inflammation and tissue damage.
Methods

Animal experiments
All animal experiments were performed in accordance with Swiss Federal animal regulations and approved by the cantonal veterinary office of Zurich. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Mice used in this study were adult 8-to 10-week-old wild-type C57BL/6 mice in a weight range of 25-30 g (Envigo Laboratories, Horst, The Netherlands), tryptophan hydoxylase-1 knocked-out mice (Tph1 À/À ) (Walther et al., 2003) , mice with selective TGF-β receptor II ablation in pancreatic epithelial cells [Ptf1a cre/+ ;
Tgf-β RII (Tgfbr2) fl/fl ] (Grabliauskaite et al., 2016) , lymphotoxin (LT) αβ-overexpressing mice (Seleznik et al., 2012) and cyclin-dependent kinase inhibitor (CDK) p21 WAF1/Cip1 knocked-out mice (p21 À/À ) (Jackson Laboratories, USA). Groups of four to five mice were kept in standard individually ventilated cages in a specific pathogen-free facility. Food and water were provided ad libitum. Only male mice were used in this study. Acute pancreatitis was induced via six i.p. injections of 50 μg·kg À1 cerulein, administered hourly on two consecutive days. Control animals received 0.9% NaCl injections. MS-275 (Selleckchem, Houston, USA) was injected daily i.p. at 20 or 40 mg·kg À1 , starting 1 day before the first cerulein injection. The concentration range of the inhibitor was chosen based on previously published in vivo studies using MS-275 in mice (Dalgard et al., 2008; Nguyen et al., 2008; Murphy et al., 2014) . Control animals received vehicle, DMSO, injections. Chronic pancreatitis was induced via six i.p. injections of 50 μg·kg À1 cerulein, administered hourly three times a week on alternate days (Monday, Wednesday, Friday) for up to 6 weeks. MS-275 was also administered three times a week on alternate days for 2 weeks starting concomitantly (preventive regimen) or 1 week after the beginning of cerulein injections (therapeutic regimen). Except for the mice harvested up to 8 h after first ceruleininjection, animals did not receive cerulein or MS-275 on the harvest day. For AIP, we used mice overexpressing LTα and LTβ that develop the disease spontaneously at 12 months of age (Seleznik et al., 2012) . Mice were examined throughout the development of pancreatitis and their health status recorded every second day on a score sheet. In the pancreatitis models used in this study only a mild form of the disease was provoked, animal weight loss did not exceed 10% and no mortality was observed. Following deep terminal anaesthesia with isoflurane, mice were killed via cardiac puncture and exsanguination.
Groups of five animals were tested for each experiment. Animals were assigned randomly to different experimental groups for all in vivo studies. Data collection and evaluation of all in vivo and in vitro experiments were performed blindly; the experimenters were unaware of group identity. dexamethasone, with daily medium replacement. For RNA quantification following de-differentiation, explants grown in 12-well plates were isolated from the collagen matrix using 10 mg·mL À1 collagenase (Sigma) for 15 min at 37°C. Samples from four replicas of each group were pooled for RNA extraction as described below. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) quantification was performed after explant isolation following collagenase treatment. Data were normalized to protein content, which was determined with the Bradford protein Assay (Bio-Rad).
RAW264.7 macrophage cells were maintained in DMEM + GlutaMAX supplemented with 10% FBS, 50 U·mL À1 penicillin and 50 μg·mL À1 streptomycin at 37°C in a 5% CO 2
atmosphere. Cells were pre-incubated with 1 μM MS-275 for 30 min and stimulated with 10 ng·mL À1 LPS for 6 h in the presence or absence of 1 μM MS-275. Cell number, cell viability and cell diameter were determined using an automated cell counter ™ , Chemometec, Allerod, Denmark).
Primary macrophages, 2x10 6 , were isolated from the peritoneum of four mice, pooled and seeded in six-well plates for 2 h and stimulated as described above for RAW cells. At the end of the treatment, cells were lysed in the plate and pooled for RNA extraction.
Immunohistochemistry
Pancreas specimens were embedded in paraffin for histological analyses, as described previously (Silva et al., 2011) . Primary antibodies used in this study were as follows: rabbit anti-Ki67 (#ab16667, Abcam, Cambridge, UK); rabbit anti-phospho-histone 3 (#2066052, Millipore, MA, USA); rabbit anti-amylase (#A8273-1VL, Sigma-Aldrich, Buchs, Switzerland); goat anti-amylase (#C20, Santa Cruz Biotechnology), rabbit anti-Sox9 (#HPA001758, Sigma-Aldrich); rabbit anti-PU. Quantitative analysis of ADM was performed as described in Bombardo et al. (2017) . Briefly, paraffin-embedded pancreas specimens were immunostained for amylase, and slides were scanned with an NDP NanoZoomer Digital Pathology Slide Scanner (Hamamatsu) and analysed for ADM lesions in a blinded fashion. ADM present in the entire pancreas slide of five mice from each treatment condition were quantified by manual counting. ADM were identified according to the following: (i) loss of amylase content; (ii) structural re-organization into tubular complexes; and (iii) stromal reaction characterized by presence of cell infiltrates. The area occupied by ADM was expressed as percentage of total pancreatic area present in each slide.
Microscopy analyses were performed on a wide-field Nikon Eclipse Ti (Amsterdam, The Netherlands). Quantification of labelled cells was performed in at least 10 randomly selected high-power fields (×200) per slide using the NIS Elements BR Analysis and Cell^P analysis software.
Western blotting
Immunoblotting was performed by homogenizing tissue samples in RIPA buffer containing protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein concentrations were determined using a Bradford protein assay (BioRad, Hercules, CA, USA). A total of 40 μg protein aliquots were separated by SDS-PAGE electrophoresis and blotted using a V3 Western Workflow system (BioRad, Hercules, CA, USA) according to the manufacturer's instructions. PVDF membranes were incubated with primary antibodies: rabbit anti-EGFR (# ab52894, Abcam); rabbit anti-α-tubulin (#2125, Cell signalling) overnight at 4°C. All results were measured by densitometry and presented as relative expression to tubulin as a reference protein.
Nuclear protein extract and HDAC activity 
Transcript analysis
Total RNA was extracted from pancreatic tissue, acinar explants and cell lines, as described previously (Graf et al., 2002) and reverse-transcribed with qScript ™ cDNA SuperMix (Quanta Biosciences). Gene expression was measured by realtime PCR on a 7500 Fast Real-Time PCR System (Applied Biosystems) using Taqman probes (Applied Biosystems). Transcript levels were normalized using 18S or HRPT RNA as a reference and expressed as ΔCt or ΔΔCt relative to the value of control samples.
Biochemical analyses of enzyme activity
Levels of amylase and glutamic-pyruvic transaminase (GPT) were measured in blood collected via heart puncture. Enzymes were measured using the Fuji Dri-Chem 4000i analyser (FUJIFILM Corporation, Tokyo, Japan). Trypsinogen activation in frozen pancreatic tissue was measured fluorometrically by using Boc-Gln-Ala-Arg-MCA as a substrate according to the method of Kawabata et al. (1988) , as described previously (Grabliauskaite et al., 2016) .
IL-6 ELISA
Levels of IL-6 were measured in cultures of RAW264.7 macrophages pre-incubated with 1 μM MS-275 for 30 min and stimulated with 10 ng·mL À1 LPS for 6 h in the presence or absence of 1 μM MS-275. IL-6 levels were quantified in culture supernatant using the Mouse IL-6 DuoSet ELISA Kit (R&D systems) following the manufacturer's instructions.
Statistics
Groups of five animals were tested for each experiment. The data are expressed as means ± SEM. The statistical significance of differences in the means of experimental groups was determined using Student's unpaired, two-tailed t-test or one-way ANOVA followed by Dunnett's post test (GraphPad Prism 4.0c; GraphPad Software, Inc.), and a probability value P<0.05 was considered statistically significant. Data and statistical analyses comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
HDAC activity is up-regulated in the pancreas during acute, chronic and autoimmune pancreatitis
To test whether HDACs are altered during acute pancreatitis, we induced the disease with serial cerulein injections according to the scheme depicted in Figure 1A . Class I HDAC1-3 transcripts were the most abundant in the untreated adult pancreas ( Figure 1B ), as previously reported (Haumaitre et al., 2008) , and the most up-regulated isoforms following pancreatitis. Increased HDAC expression was transient and returned to baseline levels over time for the majority of HDACs. HDAC activity also increased in the nuclei of pancreatic cells ( Figure 1C ), while nuclear acetylation decreased ( Figure 1D ). Increased HDAC expression and activity derived not only from pancreatic infiltration of HDAC-expressing inflammatory cells but probably also from increased HDAC expression in pancreatic parenchyma. Indeed, (i) an up-regulation of HDAC activity in the pancreas preceded the peak of immune cell infiltration (Supporting Information Figure S1A -C); (ii) increased HDAC expression was detected in acinar cells isolated 24 h after induction of pancreatitis ( Figure 1E ); and (iii) HDAC expression was comparable in control and tryptophan hydoxylase-1 knockout mice (Supporting Information Figure S2A ) or TGF-β receptor II knockout mice ( Figure S2B ), which we previously characterized with reduced (Sonda et al., 2013) or increased (Grabliauskaite et al., 2015b) inflammation respectively. Finally, HDAC up-regulation was restricted to pancreatic tissue and unchanged in other organs, including the spleen, lungs, liver and brain 24 h after induction of pancreatitis ( Figure 1F ). We then characterized HDAC expression during the course of chronic pancreatitis. Cerulein administration for up to 6 weeks, according to the scheme in Figure 1G , resulted in progressive inflammation of the organ, as measured by an up-regulation of inflammatory markers (Supporting Information Figure S3A ) and tissue damage (Supporting Information Figure S3B ). HDAC expression increased in a time-dependent manner, reaching a plateau after 4 weeks of pancreatitis, with transcripts of class I HDAC being the most abundant (Figure 1 H). Finally, we investigated whether HDAC expression is regulated during the course of autoimmune pancreatitis (AIP).
With this aim, we used transgenic mice overexpressing lymphotoxin (LT) α and β in pancreatic acinar cells that spontaneously develop AIP at 12 months of age (Seleznik et al., 2012) . Besides developing autoantibodies, these animals are characterized by increased inflammatory infiltration, expression of pro-inflammatory mediators (Supporting Information Figure S3C ) and formation of tertiary lymphoid organs in the pancreas (Supporting Information Figure S3D ). Similar to what we observed during cerulein-induced pancreatitis, the expression of HDAC, particularly of class I, was also upregulated during AIP ( Figure 1I ). Collectively, these data indicate that acute, chronic and autoimmune forms of pancreatitis trigger an increase in HDAC expression and activity in the pancreas.
Inhibition of class I HDAC with MS-275 reduces pancreatic inflammation following the induction of acute and chronic pancreatitis
As members of class I HDAC showed the highest expression during the induction of pancreatitis, we first tested their functional relevance in the acute phase of the disease by administering the selective class I inhibitor MS-275 (entinostat) according to the regimen in Figure 2A . MS-275 treatment alone did not alter either pancreatic tissue morphology (Supporting Information Figure S4A ) or induce pancreatic (Supporting Information Figure S4B ) or liver damage (Supporting Information Figure S4C ). Following the induction of pancreatitis, MS-275 abolished the increase in pancreatic HDAC activity ( Figure 2B ), without reducing the expression of HDAC transcripts (Supporting Information Figure S5 ). The indicators of early cell damage, including levels of serum amylase ( Figure 2C ) and serum GPT ( Figure 2D ), increased only following high doses of the inhibitor. Similarly, the apoptosis of acinar cells ( Figure 2E ), activation of acinar trypsinogen ( Figure 2F ) and expression of certain chemotactic proteins (Supporting Information Figure S6 ) were increased in the presence of high doses of MS-275. These data indicate that class I HDAC inhibition does not limit the initial cell damage triggered by cerulein-induced pancreatitis. Interestingly, MS-275 treatment robustly decreased the infiltration of leukocytes in the pancreas ( Figure 2G ; Supporting Information Figure S7A ), without reducing the expression of several pro-inflammatory molecules (Supporting Information Figure S7B ), and improved pancreatic morphology (Supporting Information Figure S7C ). Analysis of leukocyte populations affected by the inhibitor revealed that MS-275 decreased pancreatic levels of F4/80-positive macrophages ( Figure 2H ) and of macrophage polarization markers (M1: Cd40; M2: Arg1, Clec10) ( Figure 2I ). In addition, MS-275 treatment also reduced the presence of CD3-positive T cells, as seen by gene expression ( Figure 2J ) and histological quantification ( Figure 2K ), and reduced the expression of transcription factors typically expressed by subpopulation of T helper cells, including Th1 (Tbet), Th2 (Gata3) and Th17 (Rorγτ) ( Figure 2L ). Collectively, these data indicate that MS-275 targets the pancreatic infiltration of different leukocyte populations during the development of acute pancreatitis. The anti-inflammatory effect of MS-275 was also tested in the chronic setting of the disease after 4 weeks of cerulein injections, as this time point the pancreatitis is characterized by sustained inflammation and extended tissue damage (Supporting Information Figure S3A, B) . We compared a preventive regimen, where MS-275 was administered for 2 weeks starting concomitantly with cerulein injections, and a therapeutic regimen more relevant for a clinical setting, where MS-275 treatment started a week after induction of pancreatitis ( Figure 3A) . Both preventive and therapeutic regimens improved pancreatic morphology ( Figure 3B ), significantly reduced pancreatic infiltration of leukocytes ( Figure 3C ), including macrophages ( Figure 3D, E) , their polarization markers ( Figure 3F ) and CD3-positive T cells ( Figure 3G, H) and decreased the expression of pro-inflammatory cytokines, chemokines and adhesion molecules ( Figure 3I ).
Inhibition of class I HDAC with MS-275 alters the activation of macrophages
As MS-275 treatment reduced macrophage infiltration during both the acute and chronic phases of pancreatitis, we next investigated whether MS-275 directly affects the activation of this cell type. Activation of RAW264.7 macrophages with LPS increased the expression of HDAC1 ( Figure 4A ) and HDAC activity ( Figure 4B ). Pre-incubation with 1 μM MS-275 reduced the LPS-induced HDAC activity ( Figure 4B ) without affecting cell viability ( Figure 4C ). RAW264.7 cells respond to LPS activation by a change in cell size and morphology (McWhorter et al., 2013) . MS-275 treatment altered RAW264.7 macrophage activation, as it reduced the LPS-induced size increase ( Figure 4D) , and deregulated the expression of several inflammatory molecules; this included decreasing IL-6 levels, both at RNA and protein levels ( Figure 4E , F) and increasing IL-1β levels ( Figure 4E) . A similar deregulation of transcript expression was also observed in primary peritoneal macrophages stimulated with LPS in the presence of MS-275 ( Figure 4G ).
MS-275 treatment results in reduced acinar proliferation following acute and chronic pancreatitis
Following an inflammatory insult, acinar cells initiate a proliferation programme to regenerate the damaged tissue. MS-275 treatment decreased the number of proliferating acinar ( Figure 5A , B) and interstitial cells ( Figure 5B, C) . The expression of late cyclins A and B was also reduced (Figure 5D ), while early cyclin D and E expression was unchanged (Supporting Information Figure S8A ). Reduced proliferation was not paralleled by a general up-regulation of CDK inhibitors (CDKi). MS-275-treated pancreata showed a trend of increased expression only for the CDKi p21 cip1/WAF ( Figure 5E ), while the expression of other CDKis did not change or was reduced upon MS-275 treatment (Supporting Information Figure S8B ). We further investigated the role of p21 in the observed MS-275 phenotype, as MS-275 was reported to elicit growth arrest in cancer cells by the induction of p21 (Rosato et al., 2003; Baradari et al., 2007; Lin et al., 2011; Peulen et al., 2013) . With this aim, we tested the effect of the inhibitor in p21-deficient (p21 À/À ) mice upon induction of acute pancreatitis. Similar to what was observed in wild-type mice, MS-275 reduced macrophage infiltration ( Figure 5F ), acinar cell replication ( Figure 5H ) and late cyclin expression, without up-regulating CDKi levels ( Figure 5G ). These results suggest that the reduced cell proliferation induced by MS-275 is not a consequence of increased p21 expression. Finally, MS-275 treatment during chronic pancreatitis also resulted in reduced proliferation of acinar and interstitial cells ( Figure 5I ) and decreased expression, specifically, of late cyclins ( Figure 5J ).
Inhibition of class I HDAC reduces pancreatic tissue damage following acute and chronic pancreatitis
The reduced number of replicating acinar cells upon MS-275 treatment may be a consequence of decreased acinar injury linked to the reduced inflammatory infiltration. In support of this hypothesis, DNA damage in acinar cells, known to be triggered by inflammation (reviewed in Kidane et al., 2014) , was lower in both MS-275-treated C57BL/6 and p21 À/À mice, as shown by the quantification of γH2AX ( Figure 6A ), an early hallmark of active DNA damage. Acinar DNA damage (Grabliauskaite et al., 2015a) and macrophage infiltration (Liou et al., 2013) are also associated with the development of ADM, a transient de-differentiation of acinar cells occurring during the regenerative phase of pancreatitis. MS-275 reduced ADM formation 72 h after induction of pancreatitis ( Figure 6B ). During ADM formation, acinar cells lose their mature phenotype, including amylase content, and express progenitor-like genes, such as Sox9 (Supporting Information Figure S9 ). In the untreated condition, Sox9 is detectable in the nuclei of centro-acinar and ductal cells; following an inflammatory insult, Sox9 is also transiently expressed by acinar cells, ductules and ADM (representative pictures of Sox9 staining are shown in Figure 6C ). Staining for Sox9 revealed that MS-275 treatment reduced not only the number of ADM lesions but also the expression of Sox9 in acinar cells ( Figure 6D ). We further tested the effect of class I HDAC inhibition on tissue damage after 4 weeks of chronic pancreatitis. In the setting of chronic pancreatitis, parenchyma degradation is more evident than in the acute phase of the disease, where ADM are present as focal lesions, and it is characterized by widespread areas with clusters of interstitial cells and ADM interspersed amongst intact acinar cells containing amylase. Quantification of ADM showed that both preventive and therapeutic MS-275 regimes effectively reduced the level of ADM ( Figure 6E ) and the expression of progenitor-like genes ( Figure 6F ). Moreover, we investigated whether factors promoting acinar de-differentiation into ADM were downregulated by MS-275 treatment. The EGF-mediated signalling pathway is a potent inducer of ADM and malignant transformation (Means et al., 2005) . We found that MS-275 reduced the expression of EGFR in the pancreas at both the transcript ( Figure 6G ) and protein levels ( Figure 6H ) and the levels of its phosphorylated, active form ( Figure 6I ). 
Inhibition of class I HDAC reduces the formation of ADM in a cell autonomous manner
Reduced ADM formation upon MS-275 treatment could derive either from reduced ADM triggers, including limited production of EGFR ligands and EGFR production/activation consequent to the reduced development of inflammation, or from a direct inhibition of acinar de-differentiation into ADM by the inhibitor, independent of the presence of inflammatory cells or EGFR ligands. To test the latter hypothesis, we triggered the de-differentiation of acinar cell explants into ADM by the stimulation of EGFR with exogenous TGFα. EGFR stimulation for 5 days was accompanied by an upregulation of HDAC isoforms, with class I displaying the highest increase in expression ( Figure 7A ). MS-275 treatment reduced the formation of ADM in a dose-dependent manner ( Figure 7B ) and prevented the up-regulation of EGFR and ADM markers, such as cytokeratin 19 and Sox9 ( Figure 7C ).
This attenuation of ADM formation was not the result of acinar cell death, as cell clusters that did not form ADM were metabolically active ( Figure 7D , E). These data indicate that class I HDAC inhibition prevents acinar de-differentiation into ADM in a cell autonomous manner and that this effect is probably mediated by a down-regulation of the expression of EGFRs in acinar cells.
Discussion
In this study, we demonstrated that HDAC activity is upregulated in the pancreas during acute, chronic and autoimmune pancreatitis in different mouse strains, with a transient increase in the first and long-lasting increase in the two other forms of the disease. Moreover, pharmacological inhibition of class I HDAC ameliorated the outcome of both acute and MS-275 ameliorates the outcome of pancreatitis BJP chronic forms of pancreatitis by reducing leukocyte infiltration and limiting tissue damage and acinar cell de-differentiation into ADM. These results directly link the activity of class I HDAC with the pathophysiology of this severe disease.
MS-275 and pancreatic inflammation
The reduced inflammation observed following MS-275 treatment may result from several mechanisms. We found that, differently to what was observed upon pan-HDAC inhibitor treatment (Hartman et al., 2015) , MS-275 neither prevented the initial acinar damage nor the expression of chemokines necessary to recruit leukocytes. However, the inhibitor could diminish the recruitment of leukocyte populations, including macrophages and T cells sub-populations into the pancreas. Our results complement previous in vitro studies showing that MS-275 modifies the expression of inflammatory molecules and suppresses the migratory properties of antigen presenting cells (APCs), particularly macrophages and dendritic cells (Nencioni et al., 2007; Zhang and Schluesener, 2012) . As activated APCs regulate the activation of distinct inflammatory cell types, including T helper cells (Th1, Th2), T regulatory cells, neutrophils, monocytes and B lymphocytes, it is clear that the impairment of APC activation by HDAC inhibitors has the potential to inhibit immune processes at multiple levels. Indeed, we also observed a reduced infiltration of CD3-positive T cells upon MS-275 treatment.
While the different effect of MS treatment on individual pro-inflammatory gene expression in acute and chronic phases of pancreatitis may reflect the different timing of disease development and the contribution of both parenchymal and stromal cell populations, our results using isolated macrophages provided an overview of the effect of the inhibitor on a specific cell types. In this regard, an interesting phenomenon was the opposite effects on IL-6 (down-regulated) and IL-1β (up-regulated) in both RAW264.7 and primary macrophages. The biological significance of these different effects on cytokine expression remains to be elucidated, as their cellular effects are complex. IL-6 is a pleiotropic cytokine able to exert both pro-inflammatory and anti-inflammatory actions and to regulate macrophage polarization (Fernando et al., 2014; Mauer et al., 2014) . However, its down-regulation observed in vivo and in vitro upon MS-275 treatment, which was associated with a reduction in leukocyte infiltration in the pancreas and reduced activation of LPS-stimulated macrophages, rather supports a pro-inflammatory role of IL-6 in the tested conditions. With regard to IL-1β, while it preferentially has a pro-inflammatory role, it is worth mentioning that its up-regulation was recently shown to induce apoptosis in bacterial-infected macrophages by inducing TNF (Jayaraman et al., 2013) . Although we did not detect overt cell death of macrophages upon MS-275 treatment in the short term (h) in our experimental setting, it is possible that longterm (days) MS-275 incubation during pancreatitis may promote macrophage apoptosis and, consequently, reduce the infiltration of these cells into the pancreas.
A final consideration concerns the recently described effect of HDAC on macrophage polarization, which specify classically versus alternatively activated M1 and M2 macrophages respectively. Pharmacological and genetic studies showed that both class I and II HDAC promote an M1 phenotype (recently reviewed in Kapellos and Iqbal, 2016) . Consequently, HDAC blockade with the pan-HDAC inhibitor TSA has been reported to polarize macrophages toward an alternatively activated phenotype and to the development of mixed M1/M2 phenotypes (Cabanel et al., 2015) . However, epigenetic control of M1 and M2 phenotypes is a complex phenomenon linked to the inherent transient nature of cell polarization, as different activation states can coexist or evolve during disease progression (Martinez and Gordon, 2014) , or possibly to the different macrophage populations in the different organs. Our results support this complex regulation of macrophage physiology, as in vitro treatment with MS-275 up-regulated specific M2 markers in RAW264.7 but not in primary macrophages in our experimental conditions. In addition, in vivo treatment down-regulated both M1 and M2 markers during pancreatitis. In conclusion, further analyses are required to unambiguously clarify whether HDAC regulates macrophage polarization in the pancreas during the development of pancreatitis.
MS-275 and ADM formation
Our results revealed not only that acinar de-differentiation into ADM was accompanied by increased HDAC expression but also that class I HDAC inhibition with MS-275 was sufficient to prevent ADM formation both in vitro and in vivo. In addition, our analyses highlighted the EGFR signalling pathways as the underlying molecular mechanism targeted by class I HDAC inhibition. Specifically, we found that MS-275 treatment reduced the expression of EGFR in both in vivo and in vitro models, resulting in decreased acinar de-differentiation. These findings support the concept that increased class I HDAC activity in acinar cells is required to induce their de-differentiation into ADM by cell-autonomous mechanisms. The HDAC-mediated regulation of acinar dedifferentiation in the adult pancreas observed in the present study replicates that previously identified during pancreatic development. In this context, a global decrease in HDAC expression and activity and increase in histone acetylation were observed in the organ during the transition from embryonic to adult stages. Not only was cell differentiation into the various pancreatic cell types concomitant with HDAC downregulation, but also cell differentiation was modified by HDAC inhibition, therefore, indicating that the concerted and time-dependent activity of HDAC is a crucial regulatory factor for lineage commitment of the different pancreatic cell types (Haumaitre et al., 2008; .
Taking into consideration that (i) HDAC activity supports acinar de-differentiation during development and in the adult state following inflammatory insult, (ii) prolonged dedifferentiation of acinar cells into ADMs is detrimental for pancreatic recovery following pancreatitis and (iii) ADMs are pre-malignant lesions associated with increased risk of developing pancreatic cancer, it is tempting to speculate that HDAC inhibitors hold great potential as therapeutic agents in pancreatic inflammation. However, care has to be applied in the choice of HDAC inhibitor used, as treatment with valproic acid, an anti-epileptic drug that also has anti-HDAC activity, has been associated with the development of pancreatitis in humans (Gerstner et al., 2007) and with disease exacerbation in mice, manifested by increased inflammation, decreased proliferation and persistent acinar dedifferentiation with non-resolving ADMs (Eisses et al., 2015) .
MS-275 and acinar cell proliferation
Our results also revealed that MS-275 treatment during pancreatitis was associated with a reduced number of proliferating acinar cells. This phenotype is likely to result from reduced tissue and DNA damage in acinar cells as a consequence of the reduced infiltration of inflammatory cells. However, differentiating the exact role of HDAC in acinar proliferation during pancreatitis is precluded by the interference of the inflammatory reaction, thus we cannot exclude the possibility that MS-275 directly inhibits, to some extent, cell cycle progression in acinar cells. Increased HDAC activity is found in human pancreatic cancer cells (McCleary-Wheeler et al., 2013; Ouaissi et al., 2014) , and it is essential for cell proliferation, NF-κB activation and EMT transition (Lehmann et al., 2009; Aghdassi et al., 2012) . However, since the role of HDAC in pancreatic cancer cells cannot be directly translated to non-transformed acinar cells, additional non-tumour-based experimental models are required to address the role of HDAC in acinar cell proliferation. In this regard, we observed an upregulation of HDACs following pancreas resection, an intervention that triggers acinar proliferation with minimal levels of tissue inflammation (data not shown). As HDACs support hepatocyte proliferation following liver resection (Huang et al., 2013) , the role of HDACs in acinar cell proliferation following pancreatectomy warrants further investigation.
Conclusions
Our data directly link the expression of class I HDACs to the pathophysiology of acute and chronic pancreatitis and indicate the direct involvement of these enzymes in the development of the inflammatory response and in the dedifferentiation of acinar cells, as summarized in Figure 7E . Collectively, our data support the potential of therapeutic strategies based on inhibition of class I HDAC during pathological acute and chronic inflammatory insults of the pancreas. In addition, the up-regulation of HDAC isoforms observed during AIP encourages the exploration of the therapeutic effect of HDAC inhibition in this type of chronic pancreatitis, the treatment of which remains challenging due to the high frequency of relapses.
While the safety of several HDAC inhibitors, including MS-275, as anti-cancer treatments has been ascertained (Ryan et al., 2005) , additional clinical trials are needed to determine the correct therapeutic regimen in the setting of pancreatitis. In addition, given the existence of many HDAC isoforms, further studies with genetic knocked out models are required to understand their specificity or redundancy of functions, based on which isoform-selective inhibitors can be exploited to minimize toxicity.
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Additional Supporting Information may be found online in the supporting information tab for this article. Results are average ± SEM (n = 5), significant differences are shown for cerulein samples in the absence or presence of MS-275, *P < 0.05. Scale bars: 50 μM. Figure S8 qPCR of cyclins (A) and cell cycle regulators (B) at the indicated time after induction of pancreatitis in the presence of MS-275. Results are average ± SEM (n = 5), significant differences are shown for cerulein samples in the absence or presence of MS-275, *P < 0.05. Figure S9 Co-staining of amylase (red), Sox9 (green) and nuclei (DAPI) 72 h after induction of pancreatitis in the absence or presence of MS-275. Asterisks represent mature ADM. Note the up-regulation of Sox9 nuclear expression and the reduction of amylase content. Scale bar: 50 μM.
